Breast cancer

Patient using a mammography machine
#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Phase II trial #Phesi

Breast cancer most researched disease area for third year running

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The analysis of 65,749 recruiting clinical trials was conducted by data analytics company Phesi, as part of an annual global analysis of clinical… Read More

#Cancer Research #News #Trending News

#Breast cancer #Collaboration #Mayo Clinic #Oncology #Precision medicine #SimBioSys

US collaboration to advance precision drugs for breast cancer

Techbio SimBioSys and the Mayo Clinic have entered into a strategic collaboration to develop novel digital precision medicine solutions for breast cancer. The aim of the collaboration is to develop cloud-based clinical software tools that will support the end-to-end decision-making process for early-stage breast cancer patients, including drug selection and… Read More

#Business & Investment #News

Dr Maud Dumoux, the Franklin, and Dr Victor Bolanos-Garcia, Oxford Target Therapeutics.
#Breast cancer #Funding #Oncology #Oxford Target Therapeutics #Rosalind Franklin Institute

Cancer drug discovery company wins £50K research residency

Oxford Target Therapeutics, a company developing a promising therapy for triple negative breast cancer, is one of three UK life science companies awarded research prizes by the Rosalind Franklin Institute, based in Oxfordshire, UK. The prizes, awarded in collaboration with the Science and Technology Facilities Council… Read More

#News

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

New DDW Highlights podcast for 27 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  There have been some ground-breaking advances in women’s health this week, with new treatments… Read More

#News

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

This week in drug discovery (18-22 December) 

News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. In… Read More

#News

Breast cancer cell
#Breast cancer #Cancer research #Oncology #The Institute of Cancer Research

Discovery lights the way for new secondary breast cancer drugs

Using a novel approach, researchers from The Institute of Cancer Research, London have uncovered details of secondary breast cancer in the brain and spinal cord that may help with developing effective treatments. The study revealed for the first time that breast cancer leptomeningeal metastasis (BCLM) cells… Read More

#Cancer Research #News

Breast cancer research
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #Clinical trials #Oncology

The latest advances in breast cancer therapy

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including… Read More

#Cancer Research #News #Trending News

#AACR #Breast cancer #Breast Cancer Research Foundation #Cancer research #Harvard Medical School #Huntsman Cancer Institute

Breast cancer researchers to be recognised with SABCS award  

The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will award two researchers for their significant contributions to breast cancer research at SABCS 2023, 5-9 December, at the Henry B González Convention Center in San Antonio, Texas. 2023… Read More

#Cancer Research #News

Medical professional examining mammogram
#Breast cancer #Drug repurposing #Hormone therapy #MHRA #Oncology #UK

UK women to benefit from drug to prevent breast cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for anastrozole, to prevent breast cancer in post-menopausal women at moderate or high risk of developing the disease. The hormone treatment was already authorised for use in the treatment of breast cancer… Read More

#News #Trending News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

Breast cancer
#Arvinas #Breast cancer #Cancer research #Oncology #Pfizer #UK

ER degrader for breast cancer receives UK Innovation Passport

Arvinas and Pfizer UK have been awarded a UK Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ER (estrogen receptor) degrader. It is intended for the treatment of patients with oestrogen receptor (ER)+/ human epidermal growth factor receptor (HER)2- locally-advanced breast cancer or metastatic breast cancer. The Innovation Passport is… Read More

#News #Regulatory

Medical laboratory
#Breast cancer #Cancer research #Evgen Pharma #Oncology #Phase I trial

Phase Ib study proves efficacy of SFX-01 coated tablet formation

Evgen Pharma has revealed the final data from its Phase Ib healthy volunteer study using the company’s new enteric coated tablet formation of its lead asset SFX-01. SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. The company has already completed three trials in patients,… Read More

#Cancer Research #News

Breast cancer research
#Breast cancer #Cancer research #Immunotherapy #Oncology

Where are the advances in treatments for triple-negative breast cancer?

Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is one of the main causes of death in women. However, because these cancers are not driven… Read More

#Cancer Research #Exclusive Content

Cancer cell
#Biomarkers #Breast cancer #Cancer research #Genetics / genomics #Oncology #Personalised medicine #The Institute of Cancer Research

Genetic biomarkers could personalise therapy for TNBC

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours… Read More

#Cancer Research #News #Trending News